Kabataş, SerdarCivelek, ErdinçKaplan, NecatiSavrunlu, Eyüp CanSezen, Gülseli BerivanChasan, MouratCan, HalilGenç, AliAkyuva, YenerBoyalı, OsmanDiren, FurkanKaraöz, Erdal2021-05-042021-05-042021Kabataş, S., Civelek, E., Kaplan, N., Savrunlu, E. C., Sezen, G. B., Chasan, M., ... & Karaoz, E. (2021). Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World Journal of Experimental Medicine, 11(2), 17.2220-315Xhttps://www.doi.org/10.5493/WJEM.V11.I2.17https://hdl.handle.net/20.500.12713/1720BACKGROUND Hypoxic-ischemic encephalopathy (HIE) is a leading cause of morbidity and mortality in the adult as well as in the neonate, with limited options for treatment and significant dysfunctionality. AIM To investigate the safety and preliminary efficacy of allogeneic mesenchymal stem cells (MSCs) in HIE patients. METHODS Patients who had HIE for at least 6 mo along with significant dysfunction and disability were included. All patients were given Wharton's jelly-derived MSCs at 1 × 106/kg intrathecally, intravenously, and intramuscularly twice a month for two months. The therapeutic effects and prognostic implications of MSCs were evaluated by multiple follow-ups. Functional independence measure (FIM), modified Ashworth, and Karnofsky scales were used to assess any side effects, neurological and cognitive functions, and overall outcomes. RESULTS The 8 subjects included in the study had a mean age of 33.25 ± 10.18 years. Mean HIE exposure and mean post-HIE durations were 45.63 ± 10.18 and 19.67 ± 29.04 mo, respectively. Mean FIM score was 18.38 ± 1.06, mean modified Ashworth score was 43.5 ± 4.63, and mean Karnofsky score was 20. For the first 24 h, 5 of the patients experienced a subfebrile state, accompanied by mild headaches due to intrathecally administration and muscle pain because of intramuscularly administration. Neurological and functional examinations, laboratory tests, electroencephalography, and magnetic resonance imaging were performed to assess safety of treatment. Mean FIM score increased by 20.88 ± 3.31 in the first month (P = 0.027) and by 31.38 ± 14.69 in 12 mo (P = 0.012). The rate of patients with an FIM score of 126 increased from 14.58% to 16.57% in the first month and 24.90% in 12 mo. CONCLUSION Multiple triple-route Wharton's jelly-derived MSC administrations were found to be safe for HIE patients, indicating neurological and functional improvement. Based on the findings obtained here, further randomized and placebo research could be performed.eninfo:eu-repo/semantics/openAccessHypoxic-Ischemic EncephalopathyStem CellTransplantationWharton's JellyArticle11217292-s2.0-8510439909710.5493/WJEM.V11.I2.17Q4